Stay updated with breaking news from Robert Berman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025Topline efficacy data for VenoValve® U.S. pivotal trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024Continued progress towar...
EnVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial ...
Insiders were net buyers of Rekor Systems, Inc.'s ( NASDAQ:REKR ) stock during the past year. That is, insiders bought...
EnVVeno Medical Posts Company Highlights and Materials from 2023 VEITH ...
Operator: Good morning, ladies and gentlemen. And welcome to today’s Rekor Systems, Inc. Conference Call. My name is John, and I’ll be your coordinator for today.